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Abstract
Background: The number of patents associated with genes and proteins and the amount of
information contained in each patent often present a real obstacle to the rapid evaluation of the
novelty of findings associated to genes from an intellectual property (IP) perspective. This
assessment, normally carried out by expert patent professionals, can therefore become
cumbersome and time consuming. Here we present PatentMatrix, a novel software tool for the
automated analysis of patent sequence text entries.
Methods and Results: PatentMatrix is written in the Awk language and requires installation of
the Derwent GENESEQ™ patent sequence database under the sequence retrieval system SRS.
The software works by taking as input two files: i) a list of genes or proteins with the associated
GENESEQ™ patent sequence accession numbers ii) a list of keywords describing the research
context of interest (e.g. 'lung', 'cancer', 'therapeutics', 'diagnostics'). The GENESEQ™ database is
interrogated through the SRS system and each patent entry of interest is screened for the
occurrence of user-defined keywords. Moreover, the software extracts the basic information
useful for a preliminary assessment of the IP coverage of each patent from the GENESEQ™
database. As output, two tab-delimited files are generated which provide the user with a detailed
and an aggregated view of the results.
An example is given where the IP position of five genes is evaluated in the context of 'development
of antibodies for cancer treatment'
Conclusion: PatentMatrix allows a rapid survey of patents associated with genes or proteins in a
particular area of interest as defined by keywords. It can be efficiently used to evaluate the IP-
related novelty of scientific findings and to rank genes or proteins according to their IP position.
Background
The advent of high throughput technologies for the paral-
lel analysis of large groups of genes and proteins has chal-
lenged bioinformatics with diverse analytical needs to
exploit and interpret the large volume of data produced
[1] Many commercial and freeware software packages are
available to assist the various phases of generating and
analyzing genomics and proteomics data; from data
acquisition through processing, integration and final data
interpretation [2]. The results usually converge in one list
of genes or proteins observed to share a common feature
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like differential regulation, expression pattern and cellular
localization.
To assess the scientific novelty of the results obtained –
e.g. a list of genes found to be differentially expressed in
liver cancer – a number of publicly available text mining
tools, such as PubMatrix [3] or MedMiner [4] can be used
to explore the scientific literature in a systematic way.
PubMatrix is a web-based tool for text-based mining of
the NCBI literature search service PubMed [5], finding
associations between one or more gene names and a list
of relevant research area keywords such as 'cancer', 'liver',
'over-expressed'. Co-occurrence of a gene's name with spe-
cific keywords indicates a possible connection that can be
further explored.
To date no equivalent software tools are publicly available
to assist researchers in assessing the novelty of findings
from the viewpoint of intellectual property (IP) and thus
a detailed study of many patents related to each gene or
protein in the list is generally necessary. Given the large
number of patents usually associated with genes and pro-
teins and the amount of information contained in each
patent entry, this is a cumbersome and time consuming
activity that needs to be carried out by expert patent pro-
fessionals. PatentMatrix aims at facilitating a preliminary
patent overview by applying a PubMatrix-like approach to
the proprietary GENESEQ™ patent sequence database
(provided by Derwent Thomson Scientific [6]. The patent
entries are accessed through the Sequence Retrieval Sys-
tem (SRS, provided by Biowisdom [7]) and screened for
the occurrence of user-defined keywords. In this way it is
possible to identify connections between the genes/pro-
teins described in patents and a specific research context
as defined by the user-defined keywords. The software
also extracts from each GENESEQ™ entry the basic infor-
mation for a preliminary assessment of the gene/protein
IP status. The user is presented with a 'standard' and an
'aggregated' output providing respectively a detailed and a
more concise overview – grouped by gene – of the patent
analysis results.
Methods
The software is currently designed to analyze patent
entries from the GENESEQ™ database installed under the
sequence retrieval system SRS. SRS is one of the most
highly utilized bioinformatic platforms for data integra-
tion, analysis and display of genomics and related data. It
is widely adopted in both academic and industrial scien-
tific environments (an updated list of currently available
public SRS servers can be found in [8]). The GENESEQ™
database is mostly used in industrial environments and
contains information on nucleic acid and protein
sequences extracted from Derwent World Patents Index
basic patent documents published by 41 patent offices
worldwide. Coverage includes nucleotide sequences of 10
or more bases, all amino acid sequences of 4 or more res-
idues and nucleic probes and primers of any length. GEN-
ESEQ™ contains nucleic and amino acid sequence
information associated with the first publication of each
patent. In addition to sequence information, each GEN-
ESEQ™ entry contains structured textual information
describing the invention and many related items such as
the patent assignee, the patent status (e.g. 'pending',
'granted' etc.), the country code, the keywords associated
with the invention and many other information.
The general idea behind PatentMatrix is that of screening
the GENESEQ™ patent entries to find all the known (and
IP protected) relationships between each gene/protein
and a specific research area as described in a list of user-
defined keywords. Moreover, the software extracts the
basic information useful for a preliminary assessment of
the patent's coverage, from an IP viewpoint from the
GENESEQ™ database. The basic principles which guided
the design of PatentMatrix can be summarized as follows:
1. patents are less or more relevant with respect to a spe-
cific research area or application (e.g. the exploitation of a
gene as therapeutic target for liver cancer) depending on
the presence of crucial keywords within the patent entry
(e.g. "liver", "cancer", "therapy", "antibody").
2. "granted" patents are "stronger" than patents whose
formal acceptance is still pending (e.g. patents reported in
the database as "application", "unexamined", "granted
unexamined" etc.).
3. patents are "stronger" if the gene or the protein
sequence appears in the claims, because the invention
also covers identification of the sequence and not only a
specific application.
4. patents are "stronger" the larger the geographic area the
application covers.
PatentMatrix requires two files as input: i) a list of gene or
protein identifiers and associated patent sequence acces-
sion numbers ii) a list of user-defined keywords (Figure
1A). In order to identify the patent entries associated with
each gene or protein to be listed in the first input file,
methods based on sequence similarity such as BLAST,
FASTA or others can be used [9]. The usage of our software
requires that one first retrieves the patent sequence acces-
sion numbers associated with the list of gene/protein
identifiers, using one of the methods mentioned above.
Examples of formats for the two input files are listed
below:Source Code for Biology and Medicine 2007, 2:4 http://www.scfbm.org/content/2/1/4
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Input file 1 (genes/proteins of interest and related patent
identifiers):












All patent entries from the input list of input file 1 are
retrieved from the GENESEQ™ database and screened for
each of the keywords provided in input file 2. During
A Software architecture Figure 1
A Software architecture. PatentMatrix takes as input two files: i) a list of genes or proteins with the associated patent sequence 
accession numbers ii) a list of keywords describing the research context of interest. Each IP entry is retrieved from the GEN-
ESEQ™ database through 'getz' calls to the SRS system. B 'standard' output file. The 'standard' output is a tab delimited table 
displaying for each IP entry the results of the analysis. Hyperlinks to the Entrez Gene to the GENESEQ™ databases are availa-
ble. The individual output fields are described in the "Methods" section.Source Code for Biology and Medicine 2007, 2:4 http://www.scfbm.org/content/2/1/4
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parsing the position of text containing the gene/protein
sequence within the patent entry is also checked (e.g. in
"claims", disclosure", "examples"). Moreover, informa-
tion describing the applicant's name, applicant country
and the patent status (e.g. "pending", "granted" etc.) is
extracted. This information can be very useful for a pre-
liminary assessment of the gene's IP status, according to
points 2, 3 and 4 illustrated above.
A matrix is then generated ('standard' output file) with
records of individual patent sequence accession numbers,
annotated with the following fields (Fig. 1B):
- Gene/Protein ID: identifier of the gene/protein
- Gene/Protein ID Link: hyperlink to the Entrez gene/pro-
tein entry
- Patent Accession: accession number of the GENESEQ™
entry
- Patent Accession Link: hyperlink to the SRS GENESEQ™
entry
- Patent ID: official patent identifier
- Sequence Location: textual position of the gene/protein
sequence within the GENESEQ™ entry (e.g. "claim", dis-
closure", "example")
- Patent Assignee: the entity (person, company, institu-
tion) by whom the patent was submitted
- Patent status: e.g. "granted", "application", "unexam-
ined" etc.
- Patent country: indicates the geographic coverage of the
patent (e.g. Europe, US, etc.)
In addition to the fields listed above, a column is added
for each of the user-defined keywords provided as input.
These columns describe the occurrences of each input key-
word in the patent entry description.
An 'aggregated' second output file can be generated by
using an auxiliary script called PatentMatrixAggregate. The
'aggregated' output combines the results from all the asso-
ciated patents and keywords for each gene/protein in the
input list, thus providing the user with a more concise
overview of the results (Fig. 2).
Results and Discussion
The diagram in Fig. 1A illustrates the data flow: the soft-
ware takes as input two files from the command line: i) a
list of gene or protein identifiers and their related patent
sequence accession numbers ii) a list of user-defined key-
words. The software then performs queries to the GEN-
ESEQ™ database through SRS [10] using the SRS
command line query language 'getz'. For each record of
the first input file, the corresponding patent entry in SRS
is accessed and examined as illustrated above. It is impor-
tant to notice that the GENESEQ™ database is designed in
a sequence-centered manner and each patent entry refers
to an individual nucleic or amino acid sequence. This
implies that if one patent reports different sequences, this
translates into different GENESEQ™ patent entries. There-
fore all the information extracted from a GENESEQ™ pat-
ent entry can be unambiguously referred to the associated
gene or protein sequence.
A tab delimited file containing the results of the analysis
for each gene/protein patent entry is generated as standard
output. The aggregated output (described in previous sec-
tion) can be generated by using the auxiliary script 'Pat-
entMatrixAggregate'.
In addition to keyword counts, measures such as odd
ratios or p-values could be utilized to represent the devia-
tion of keyword occurrence from average values calculated
'aggregated' output file Figure 2
'aggregated' output file. PatentMatrixAggregate is used to 
aggregate the 'standard' output allowing a global "gene cen-
tric" view of the IP status. For each gene/protein the total 
number of keywords found in the associated patent entries is 
displayed.Source Code for Biology and Medicine 2007, 2:4 http://www.scfbm.org/content/2/1/4
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over the entire database, or in a random sample. For
example, if the word "cancer" is found 20 times associated
to gene X and the average count over the entire patent
database is 22, the – count does not deviate much from
the average. Nevertheless, the observed count of 20 indi-
cates that for gene X there is probably already IP related to
cancer. We have therefore chosen to directly report the
keyword count, leaving the task of evaluating the results to
the user according to individual criteria. This measure,
although simple, can be very effective in singling out
those genes or proteins from a long list for which there is
only limited IP information for a role in a given area of
research.
As the semantic linking the keywords with genes/proteins
in each patent entry is not taken into account, a number
of false positives is to be expected. It is therefore impor-
tant to emphasize that the information provided by Pat-
entMatrix is not intended as conclusive or as a substitute
for an expert and detailed evaluation of the single patent
entries. However, we believe this type of general IP statis-
tics to be very useful in prioritizing a long list of genes/
proteins for "patent novelty" in a given area of research.
Our software is designed to analyze the patents provided
as input in a sequential manner, and can be scaled up lin-
early, with virtually no limits to the length or number of
input patents. However, we envisage PatentMatrix as
being normally used with a number of patents related to
between 50 and 1,000 genes/proteins, a typical result list
of a proteomics (e.g. LC-MS) or genomics (e.g. DNA
microarray) study.
PatentMatrix is written in the Awk scripting language [11]
and requires a UNIX machine where an SRS installation,
including the GENESEQ™ database, is present. This tool is
available on request from the authors, and the package
also includes examples and full documentation. As Awk is
a standard Unix interpreted script language, PatentMatrix
is fully compatible with any Unix system and does not
require any specific installation procedure. A future devel-
opment of PatentMatrix could be access through a graph-
ical user interface (GUI) to improve its user-friendliness.
However, an important advantage of keeping the software
in the command-line version lies in the ease of integration
with other software applications, especially from the per-
spective of using this tool as part of a more complex work-
flow for the analysis of collections of genes/proteins.
Empirical demonstration
To briefly illustrate the capabilities of PatentMatrix, we
describe the analysis results derived from a short list of
genes (gene IDs: '41', '109', '152', '366','775', respectively
referring to gene names ACCN2, ADCY3, ADRA2C,
AQP9, CACNA1C) for which a total number of 99 patent
entries are available in the GENESEQ™ database. The gene
IDs and the corresponding patent accession numbers are
listed in the first input file, as described in the 'methods'
section.
The research area we chose is the development of antibod-
ies for cancer treatment. In order to represent this area we
have arbitrarily chosen the keywords: 'cancer', 'tumor',
'liver', 'over-expressed', 'antigen', 'vaccine', 'monoclonal',
'antibody', 'therapeutic', 'oncogene'. These keywords are
listed in the second input file.
The idea here is to evaluate the IP position of these genes
with respect to their application in the area of liver cancer
therapeutic treatment with vaccine and/or monoclonal
antibodies. In Fig. 1B, a subset of the output file describ-
ing part of the results obtained for gene IDs '41'and '109'
is illustrated. A number of patent entries related to 'cancer'
can be recognized and, among them, one entry containing
the words 'therapeutic' and 'liver' can be identified. The
user can then check the additional information displayed
and, if necessary, can access the full patent entry by using
the available hyperlink.
By using the 'PatentMatrixAggregate' script the 'standard'
output can be then summarized in the 'aggregated' output
file, as shown in Fig. 2. From this file it appears evident
that the gene with ID 109 (ADCY3) is that which has the
highest number of patent entries with cancer related key-
words: 6 of them with the keyword 'vaccine', 2 with 'anti-
body' and 2 with 'therapeutic'. Obviously an accurate and
in-depth study of the single patents related to each gene is
needed for a sound assessment of the IP status of the
genes. However, this preliminary overview already indi-
cates that the gene ADCY3, in comparison to the others, is
that with the greater likelihood of being protected from
the IP standpoint in the areas of application explored.
Conclusion
We have shown here that PatentMatrix efficiently explores
the potential links between genes/proteins and patents, in
a research area of interest defined by keywords. Being
applicable to large lists, the tool is well suited to being
adopted as part of a more extensive workflow of analysis
(e.g. in a target identification/validation process).
Although this semi-automatic approach does not and is
not intended to substitute thorough patent evaluation by
experts, it provides the user with a first-line straightfor-
ward and integrated overview of the often vast amount of
existing context-specific patent literature. Finally, the sys-
tematic and structured mining of patents describing genes
and proteins can also be exploited as a complementary
resource to explore additional scientific information often
not published in the literature.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Source Code for Biology and Medicine 2007, 2:4 http://www.scfbm.org/content/2/1/4
Page 6 of 6
(page number not for citation purposes)
Authors' contributions
Armin Lahm has made substantial contributions to the
conceptualization of the method and to data interpreta-
tion and drafting the manuscript. Emanuele de Rinaldis
has conceptualized the method, implemented and tested
the automated workflow and written the final version of
the paper. Both authors read and approved the final man-
uscript.
Acknowledgements
We would like to thank Paolo Monaci, Giovanni Galfre', Mike Rowley and 
Paolo Uva for useful discussions. We also wish to thank Sabrina Grechi and 
Janet Clench for the linguistic revision of the text. This work was supported 
in part by a grant from Ministero dell'Istruzione, dell' Università e della 
Ricerca
References
1. Ilyin SE, Bernal A, Horowitz D, Derian CK, Xin H: Functional Infor-
matics: convergence and integration of automation and bio-
informatics.  Future Medicine 2004, 5(6):721-730.
2. Dragici S: Data analysis tools for DNA microarrays.  Chapman
& Hall/CRC; 2003. 
3. Becker KG, Hosack DA, Dennis G Jr, Lempicki RA, Bright TJ, Cheadle
C, Engel J: PubMatrix: a tool for multiplex literature mining.
BMC Bioinformatics 2003, 4(1):61.
4. Tanabe L, Scherf U, Smith LH, Lee JK, Hunter L, Weinstein JN: Med-
Miner: an Internet text-mining tool for biomedical informa-
tion, with application to gene expression profiling.
Biotechniques 1999, 27(6):1210-4. 1216-7
5. PubMed   [http://www.ncbi.nlm.nih.gov/entrez/query/static/over
view.html]
6. GENESEQ™   [http://scientific.thomson.com/products/geneseq/]
7. Biowisdom   [http://www.biowisdom.com]
8. Lion bioscience   [http://downloads.lionbio.co.uk/publicsrs.html]
9. Dufresne G, Takacs L, Heus HC, Codani JJ, Duval M: Patent
searches for genetic sequences: How to retrieve relevant
records from patented sequence databases.  Nature Biotechnol-
ogy 2002, 20:1269-1271.
10. Etzold T, Ulyanov A, Argos P: SRS: information retrievalsystem
for molecular biology data banks.  Methods Enzymol 1996,
266:114-128.
11. Gawk   [http://www.gnu.org/software/gawk/gawk.html]